The pharmacodynamics of tinzaparin in healthy volunteers.
We report the pharmacodynamic properties of tinzaparin (175 U/kg antifactor Xa) given as a single daily administration for 5 consecutive days to 14 healthy volunteers as a known safe, effective treatment of deep vein thrombosis and pulmonary embolism. The Cmax for antifactor Xa (0.87 +/- 0.15 U/ml) was associated with a 2.4 +/- 0.5-fold prolongation of the activated partial thromboplastin time (APTT) and a high antithrombin activity (0.38 +/- 0.1 U/ml). The Cmax value of antifactor Xa was 1.5- and twofold lower than those generated by similar doses of nadroparin and enoxaparin respectively. The clearance of antifactor Xa activity (1.29 +/- 0.2 l/h) was 1.5- and twofold greater than those reported for nadroparin and enoxaparin respectively. These results indicated that the antithrombotic and prohaemorrhagic effects of a low molecular weight heparin were independent from the absolute levels of antifactor Xa activities and from the prolongation of the APTT.
Cambus
Jean-Pierre
JP
Laboratoire d'Hématologie, Hôpital Rangueil, Toulouse, France.
Saivin
Sylvie
S
Heilmann
Jean-Jacques
JJ
Caplain
Henri
H
Boneu
Bernard
B
Houin
Georges
G
D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000494:pharmacology; D000991:Antithrombins / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000097:blood / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D000078222:Tinzaparin
D000991:Antithrombins; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D000990:Antithrombin III